Breaking News Instant updates and real-time market news.

DPS

Dr Pepper Snapple

$86.80

1.5507 (1.82%)

, PEP

PepsiCo

$102.75

0.49 (0.48%)

12:08
11/22/16
11/22
12:08
11/22/16
12:08

On The Fly: Top stock stories at midday

Stocks began the session with gains, pushing the Dow, S&P, and Nasdaq further into record territory. In the process, the Dow cleared 19,000 and the S&P went above 2,200, though both have pulled back and dropped back below those milestone levels. Oil prices also started strong and fell across the flat line into negative ground, though the commodity has been able to limit its slide and is down about 1% to just below $48 per barrel near midday. ECONOMIC NEWS: In the U.S., existing home sales climbed 2.0% to a 5.6M rate in October, the strongest since early 2007. The Richmond Fed's manufacturing index rose to 4 in November, an 8 point increase. COMPANY NEWS: Dr Pepper Snapple (DPS) announced that it has reached an agreement to acquire Bai Brands and its complete portfolio of premium antioxidant infused beverages. The cash purchase price of $1.7B includes a tax benefit of approximately $400M on a net present value basis and will be financed through new unsecured notes and short term commercial debt. Following the announcement, shares of Dr Pepper Snapple rose almost 2%. In other beverage industry M&A news, PepsiCo (PEP) announced that it has entered into a definitive agreement to acquire KeVita, a North American creator of fermented probiotic and kombucha beverages. Upon closing, KeVita will continue to operate independently with its production and bottling facilities located in Oxnard, California... Shares of Medtronic (MDT) have dropped 10% near noon after the medical device maker reported weaker than expected quarterly revenue driven by slower growth in its diabetes and heart product units. Additionally, the company cut its adjusted earnings forecast for 2017. MAJOR MOVERS: Among the notable gainers was Burlington Stores (BURL), which advanced over 14% after the company announced better than expected third quarter results. Also higher was Chico's (CHS), which gained about 11% after beating earnings per share estimates for the quarter. Additionally, Dollar Tree (DLTR) rose almost 10% after the discount store chain reported stronger than expected quarterly earnings and lifted its guidance. Among the noteworthy losers was Palo Alto Networks (PANW), which slid 13% after the company reported first quarter results. While revenue increased in the latest quarter, the growth was Palo Alto Networks' slowest pace as a public company and the deceleration is expected to continue. Also lower was Patterson Companies (PDCO), which slipped almost 20% after the company reported worse than expected quarterly results, lowered its guidance for 2017 and announced it has elected not to extend its exclusivity selling agreement with Dentsply Sirona (XRAY) beyond September 2017. Additionally, FireEye (FEYE) dropped about 7% after Goldman Sachs downgraded the stock to Sell, saying that the Internet security company's transitions create medium-term risks for the stock. INDEXES: Near midday, the Dow was up 11.71, or 0.06%, to 18,968.40, the Nasdaq was up 2.24, or 0.04%, to 5,371.10, and the S&P 500 was down 2.76, or 0.13%, to 2,195.42.

DPS

Dr Pepper Snapple

$86.80

1.5507 (1.82%)

PEP

PepsiCo

$102.75

0.49 (0.48%)

MDT

Medtronic

$72.34

-8.237 (-10.22%)

BURL

Burlington Stores

$84.33

10.15 (13.68%)

CHS

Chico's

$15.52

1.525 (10.90%)

DLTR

Dollar Tree

$81.99

0.08 (0.10%)

PANW

Palo Alto Networks

$140.51

-20.555 (-12.76%)

PDCO

Patterson Companies

$47.51

1.02 (2.19%)

XRAY

Dentsply Sirona

$59.88

-0.28 (-0.47%)

FEYE

FireEye

$13.87

0.24 (1.76%)

  • 22

    Nov

  • 22

    Nov

  • 22

    Nov

  • 22

    Nov

  • 22

    Nov

  • 22

    Nov

  • 29

    Nov

  • 05

    Dec

  • 08

    Dec

  • 08

    Dec

  • 09

    Dec

  • 13

    Dec

DPS Dr Pepper Snapple
$86.80

1.5507 (1.82%)

10/04/16
BERN
10/04/16
NO CHANGE
Target $92
BERN
Market Perform
Dr Pepper Snapple top line at risk if Bai business lost, says Bernstein
After Reuters reported that Bai, the seller of antioxidant infusion drinks that is allied with Dr Pepper Snapple and in which the beverage company has a minority equity investment, is exploring a potential sale, Bernstein analyst Ali Dibadj said the firm's analysis suggests that the loss of Bai from Dr Pepper's system could result in a meaningful 100 basis point drag on the company's top line. Allied brands distributed by Dr. Pepper, like Bai, have been driving at least half of its topline growth recently, added Dibadj, who keeps a Market Perform rating on the stock.
10/04/16
EVER
10/04/16
DOWNGRADE
EVER
Hold
Dr Pepper Snapple downgraded to Hold from Buy at Evercore ISI
10/04/16
10/04/16
DOWNGRADE

Hold
Dr Pepper Snapple downgraded on Bai Brands potential sale at Evercore ISI
As previously reported, Evercore ISI downgraded Dr Pepper Snapple to Hold form Buy. Analyst Robert Ottenstein said reports that Bai Brands is looking for a new owner are credible and could change investor's psychology on the stock and its Allied Brands business. The analyst believes Bai Brands will get sold and result in loss of distribution, negatively impacting earnings by 20c-25c. Further, Ottenstein said consumers are increasingly concerned about sugar and it is on the radar screen of local governments as a revenue source.
10/04/16
10/04/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Wells Fargo (WFC) downgraded to Underperform from Market Perform at Raymond James with analyst David Long saying the fallout from the unauthorized account openings will result in continued under performance. The analyst said several additional investigations, lawsuits, and fines have been announced, resulting in a still cloudy outlook. 2. Kinder Morgan (KMI) downgraded to Hold from Buy at Stifel analyst Selman Akyol citing valuation. 3. GrubHub (GRUB) downgraded to Hold from Buy at Stifel with analyst John Egbert citing valuation. 4. Dr Pepper Snapple (DPS) downgraded to Hold from Buy at Evercore ISI with analyst Robert Ottenstein saying reports that Bai Brands is looking for a new owner are credible and could change investor's psychology on the stock and its Allied Brands business. 5. Dollar Tree (DLTR) downgraded to Neutral from Buy at Cleveland Research with the firm saying sales trends appear to have slowed further at Family Dollar as the company struggles with increased price competition, difficult comps, and strategy headwinds. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
PEP PepsiCo
$102.75

0.49 (0.48%)

09/15/16
FBCO
09/15/16
INITIATION
FBCO
Outperform
PepsiCo initiated with an Outperform at Credit Suisse
09/15/16
FBCO
09/15/16
INITIATION
Target $121
FBCO
Outperform
PepsiCo initiated with an Outperform at Credit Suisse
Credit Suisse analyst Laurent Grandet initiated coverage on PepsiCo with an Outperform and a $121 price target. Grandet does not believe the market is giving PepsiCo enough credit for Frito-Lay's marketing and financial strength and the rebalancing of the US beverages portfolio towards faster growing noncarbonated beverages.
09/16/16
09/16/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. GoPro (GPRO) initiated with a Buy at BofA/Merrill. 2. JetBlue (JBLU) initiated with an Outperform at Imperial Capital. 3. PepsiCo (PEP), Dr Pepper Snapple (DPS), and Monster Beverage (MNST) were initiated with an Outperform at Credit Suisse, while the firm initiated Boston Beer (SAM) with an Underperform. Credit Suisse also initiated Coca-Cola (KO) and Constellation Brands (STZ) with a Neutral. 4. lululemon (LULU) initiated with a Positive at Susquehanna. 5. Target (TGT) coverage assumed with a Neutral at Credit Suisse. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
09/29/16
STFL
09/29/16
DOWNGRADE
STFL
Hold
Coca-Cola downgraded following Pepsi results at Stifel
As noted earlier, Stifel analyst Mark Swartzberg downgraded Coca-Cola (KO) to Hold from Buy. The analyst downgraded the stock after Pepsi (PEP) reported better than expected Q3 results. The analyst says that Coca-Cola's and Pepsi's organic EPS growth appears to be similar, but he believes that Pepsi is less vulnerable to foreign exchange fluctuations. Additionally, he believes that Coca Cola European Bottlers (CCE) is a better investment than Coca-Cola because of the large amount of revenue synergies which that Coca Cola European Bottlers has identified.
MDT Medtronic
$72.34

-8.237 (-10.22%)

11/15/16
LEER
11/15/16
NO CHANGE
LEER
Edwards Lifesciences, Medtronic selloff overdone, says Leerink
Leerink analyst Danielle Antalffy notes that both Edwards Lifesciences (EW) and Medtronic (MDT) traded down in reaction to a presentation of the German Aortic Valve Registry data in intermediate risk patients. However, she believes the selloff is overdone, with no change to her estimated total addressable transcatheter aortic valve replacement, or TAVR, market opportunity as there are key baseline characteristic differences between both the surgical valve and TAVR groups that skews the data, and randomized controlled clinical trial data trumps registry data.
11/14/16
PIPR
11/14/16
NO CHANGE
PIPR
Overweight
Piper would buy TAVR names on 'GARY' registry weakness
Piper Jaffray analyst Brooks West attributes today's weakness in transcatheter aortic valve replacement makers Medtronic (MDT), Edwards Lifesciences (EW) and Boston Scientific (BSX) to a presentation at the AHA meeting of data from the German Aortic Valve Registry, or "GARY," comparing one year outcomes for patients at intermediate surgical risk who underwent isolated interventional versus conventional surgical aortic valve replacement for severe symptomatic aortic valve stenosis. The data showed a surprisingly negative result, but prior debates around the "GARY" led to no impact on TAVR volumes and West is "skeptical of the results," he tells investors. The firm has Overweight ratings on all three stocks mentioned above.
11/14/16
EVER
11/14/16
NO CHANGE
EVER
Medtronic, Edwards Lifesciences defended at Evercore ISI
11/02/16
BMOC
11/02/16
NO CHANGE
BMOC
Dexcom still has positive catalysts, says BMO Capital
After Dexcom reported higher than expected Q3 revenue but said it does not expect its 2016 revenue to come in above its previous guidance range, BMO Capital analyst Joanne Wuensch says that the company's Q4 and 2017 results will probably be negatively impacted by Medtronic's (MDT) upcoming MiniMed 670G product. Nonetheless, the analyst says that the pending non-adjunctive label for Dexcom's CGM "can make waves," while it has "ample" room for growth in its "vastly underserved" market, as its "technology is nowhere near its full potential." The analyst cut her price target on the shares to $90 from $112 but keeps an Outperform rating on the stock.
BURL Burlington Stores
$84.33

10.15 (13.68%)

11/09/16
COWN
11/09/16
NO CHANGE
Target $90
COWN
Outperform
Burlington Stores short report has several unfair characterizations, says Cowen
Cowen analyst John Kiernan noted Burlington faced several negative headlines on third party credit card data, poor weather trends, and retail traffic. He also said a recent "short report" regarding Burlington had several unfair characterizations. Kiernan maintained his Outperform rating and $90 price target on Burlington Store shares.
09/30/16
GUGG
09/30/16
INITIATION
GUGG
Neutral
Burlington Stores initiated with a Neutral at Guggenheim
09/26/16
BOFA
09/26/16
NO CHANGE
Target $95
BOFA
Buy
Burlington Stores price target raised to $95 from $90 at BofA/Merrill
BofA/Merrill analyst Lorraine Hutchinson believes Burlington will generate strong comps in 2H 2016 due to positive supply chain dislocations, the Hanjin bankruptcy causing competitor product delays, and store closings at Macy's. The analyst reiterates his Buy rating on Burlington and raised its price target to $95 from $90.
08/26/16
08/26/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Seaport Global upgraded PetroQuest (PQ) to Buy and raised its price target to $5 from $4, citing reduced near-term balance sheet concerns and a potential Cotton Valley joint-venture partner by year-end. 2. MKM Partners upgraded Burlington Stores (BURL) to Buy from Neutral and increased its price target to $94 from $73. The analyst said two quarters of comp beats demonstrate strong momentum and sees catalysts for continued comp growth, continued refinement of the offprice model, outsized growth in home and beauty, and gross margin expansion. 3. Credit Suisse upgraded Petrobras (PBR) to Neutral and raised its price target to $8.60 from $2. The analyst believes management can add value through cost and capex cuts, divestments, fuel pricing, and strategic changes. 4. HSBC upgraded Southern Copper (SCCO) to Buy and raised its price target to $31.50 from $27. The analyst believes copper prices have bottomed and expects better production growth, higher by-product commodity prices, increasing free cash flow, and an improving balance sheet. 5. Northcoast upgraded A. Schulman (SHLM) to Buy and established a $30 price target. The analyst said risk/reward is favorable and sees catalysts from the reintroduction of Joe Gingo as CEO and his business plan review. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
CHS Chico's
$15.52

1.525 (10.90%)

11/16/16
NOMU
11/16/16
DOWNGRADE
NOMU
Neutral
Chico's downgraded to Neutral from Buy at Nomura
11/16/16
11/16/16
DOWNGRADE

Neutral
Chico's downgraded to Neutral due to valuation at Nomura
As previously reported, Nomura downgraded Chico's to Neutral from Buy citing valuation.
11/15/16
KEYB
11/15/16
DOWNGRADE
KEYB
Sector Weight
Chico's downgraded to Sector Weight from Overweight at KeyBanc
11/15/16
KEYB
11/15/16
DOWNGRADE
KEYB
Sector Weight
Chico's downgraded to Sector Weight from Overweight at KeyBanc
KeyBanc analyst Edward Yruma downgraded Chico's FAS to Sector Weight citing valuation with the stock up 25% since November 4.
DLTR Dollar Tree
$81.99

0.08 (0.10%)

11/15/16
JRCO
11/15/16
UPGRADE
JRCO
Accumulate
Dollar Tree upgraded to Accumulate from Hold at Johnson Rice
11/14/16
UBSW
11/14/16
NO CHANGE
Target $90
UBSW
Buy
Dollar Tree valuation is quite favorable, says UBS
UBS analyst Michael Lasser said Dollar Tree's valuation remains favorable. Lasser said top-line trends for Q3 were probably subdued but with the shares trading at a discount and its PE trading at just a sight premium to the S&P, soft trends will be reflective of a tough environment rather than a change in productivity. The analyst said margins should continue to gain as synergies with is Family Dollar acquisition accelerate. Lasser reiterated his Buy rating and $90 price target on Dollar Tree shares.
10/13/16
10/13/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Aaron's (AAN) initiated with a Buy at Jefferies. 2. eBay (EBAY) and Etsy (ETSY) coverage assumed with a Neutral at Wedbush. 3. Five Below (FIVE) and Dollar Tree (DLTR) were initiated with an Overweight at KeyBanc while the firm initiated Dollar General (DG) with a Sector Weight. 4. Baxter (BAX) initiated with an Outperform at Wells Fargo. 5. Symantec (SYMC) initiated with an Outperform at FBN Securities. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
11/15/16
11/15/16
UPGRADE

Accumulate
Dollar Tree upgraded to Accumulate on Family Dollar progress at Johnson Rice
As previously reported, Johnson Rice upgraded Dollar Tree to Accumulate from Hold. Analyst David Mann has increased confidence in the long-term transformation at Family Dollar, the strong management team, lower investor expectations, and more attractive valuation.
PANW Palo Alto Networks
$140.51

-20.555 (-12.76%)

11/22/16
PIPR
11/22/16
NO CHANGE
Target $178
PIPR
Overweight
Palo Alto Networks still posting 31% revenue growth, says Piper Jaffray
Piper Jaffray analyst Andrew Nowinski points out that despite the "disappointing" Q1 results, Palo Alto Networks (PANW) is still generating 31% revenue growth, which is three-times above closest competitor Cisco (CSCO). He recommends investors hold the stock through the selling pressure. Nowinski lowered his price target for Palo Alto shares to $178 from $184 and keeps an Overweight rating on the name.
11/22/16
MAXM
11/22/16
NO CHANGE
Target $185
MAXM
Buy
Palo Alto Networks technology still 'best-in-class,' says Maxim
Maxim analyst Nehal Chokshi blames Palo Alto Networks' Q1 revenue miss and softer Q2 guidance to an extension in its large deal sales cycle. However, despite seeing limited upside for the remainder of FY17, he continues to believe that Palo Alto has a best-in-class network security capability and keeps a Buy rating and $185 price target on the shares.
11/22/16
PACS
11/22/16
NO CHANGE
PACS
Palo Alto Networks long-term opportunity still positive, says Pacific Crest
After Palo Alto reported weaker than expected results, Pacific Crest analyst Rob Owens blames the miss on "extended deal cycles requiring additional approval." .However, the analyst continues to believe that its growth is "impressive," and he thinks that it still has one of the best longer term outlooks of any IT security company.He keeps a $190 price target and an Overweight rating on the shares.
11/22/16
STFL
11/22/16
NO CHANGE
STFL
Buy
Palo Alto Networks long-term thesis remains intact, says Stifel
Stifel analyst Gur Talpaz said Palo Alto Networks missed Q1 due to revenue and billings estimates due to an elongated sales cycle that resulted in some larger deals slipping into Q2. The analyst sees a relatively healthy enterprise security spending environment but with additional deal scrutiny and higher levels of discounting among Palo Alto's primary competitors. However, Talpaz is encouraged by improving traction of the company's Traps and VM-Series solutions and views Q1 results as a hiccup and said his long-term Buy thesis is intact.
PDCO Patterson Companies
$47.51

1.02 (2.19%)

11/01/16
NRCS
11/01/16
NO CHANGE
NRCS
Amazon.com should partner with Patterson Companies, says Northcoast
Northcoast said Amazon.com (AMZN) has a strong interest in entering the dental market and has spent time and resources attempting to build relationships with manufacturers and distributors to gain product procurement, which so far has been unsuccessful. The firm's analyst said Patterson (PDCO) is aggressively trying to reinvent how dental distribution will occur in the future and is building a new IT backbone, making huge investments in technical service. Northcoast said Patterson is on a path to disrupt the industry and could accelerate this effort with a partnership with Amazon. The firm continues to view Patterson as undervalued, with out without Amazon, and recommends investors build positions at this time.
10/05/16
UBSW
10/05/16
INITIATION
Target $48
UBSW
Neutral
Patterson Companies initiated with a Neutral at UBS
Target $48.
11/22/16
PIPR
11/22/16
NO CHANGE
PIPR
Patterson cancellation a positive for Dentsply, says Piper Jaffray
Piper Jaffray analyst Matt O'Brien believes Patterson Companies (PDCO) cancelling its exclusive selling agreement with legacy Sirona products beyond September 2017 as positive for Dentsply Sirona (XRAY). The move is unsurprising given the changing industry dynamics, O'Brien tells investors in a research note. He points out that the initial exclusive agreement was established in 1998. Assuming Henry Schein (HSIC) starts selling legacy Sirona equipment, the cancellation is a positive for Dentsply as this will ultimately allow the company to increase cross-selling opportunities with those customers, O'Brien argues. He's been calling for a cancellation of the exclusive selling agreement with Patterson saying Dentsply has been adamant about realizing sales synergies through increased cross-selling opportunities. The analyst reiterates an Overweight rating on Dentsply with a $70 price target. Patterson in pre-market trading is down 17% to $39.20 after reporting a decline in North American dental consumables sales of 2.5%. Dentsply shares are down 2% to $58.40.
11/21/16
BARD
11/21/16
NO CHANGE
BARD
Outperform
Baird expects Amazon.com distribution announcement with Patterson
Following industry conversions, Baird analyst Jeff Johnson expects Patterson Companies (PDCO) to announce an Amazon.com (AMZN) distribution agreement tomorrow. What the analyst hadnt considered and is now hearing is that Amazon could fulfill orders placed through Patterson's order portal, lowering Patterson's fulfillment costs and given the company breathing room as it pursues DSO deals. Johnson rates Patterson a Neutral with a $48 price target.
XRAY Dentsply Sirona
$59.88

-0.28 (-0.47%)

09/22/16
09/22/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: Packaging Corp. (PKG) initiated with a Sell at Goldman. 2. Netlist (NLST) initiated with a Buy at B. Riley. 3. Weyerhaeuser (WY) initiated with a Conviction Buy at Goldman. 4. bluebird bio (BLUE) reinstated with a Buy at Roth Capital. 5. Dentsply Sirona (XRAY) initiated with a Neutral at JPMorgan. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
11/01/16
11/01/16
UPGRADE
Target $69

Overweight
Dentsply Sirona upgraded on growth, valuation at Morgan Stanley
As previously reported, Morgan Stanley upgraded Denstply Sirona to Overweight from Equal Weight and raised its price target to $69 from $65. Analyst Steve Beuchaw said Densply's relative valuation weakness positions the company for better performance despite negative dental market sentiment. He expects Dentsply's organic growth to accelerate in 2017 driven by digital dentistry adoption, a focus on commercial headcount, easing digital equipment comps, and revenue synergies. Beauchaw expects the company's double digit free cash flow growth potential to improve investor sentiment.
11/01/16
MSCO
11/01/16
UPGRADE
MSCO
Overweight
Dentsply Sirona upgraded to Overweight from Equal Weight at Morgan Stanley
FEYE FireEye
$13.87

0.24 (1.76%)

10/24/16
10/24/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. AT&T (T)downgraded to Hold from Buy at Drexel Hamilton, and to Market Perform from Outperform at Cowen. 2. Time Warner (TWX) downgraded to Neutral from Outperform at Credit Suisse, to Neutral from Buy at MKM Partners, to Neutral from Conviction Buy at Goldman, to Neutral from Outperform at Macquarie, to Hold from Buy at Pivotal Research, to Neutral from Overweight at Atlantic Equities, to Neutral from Buy at MoffettNathanson, and to Sector Perform from Outperform at RBC Capital. 3. Everyday Health (EVDY) downgraded to Neutral from Outperform at Credit Suisse, to Hold from Buy at SunTrust, and to Market Perform from Outperform at Leerink. 4. Reynolds American (RAI) downgraded to Underperform from Outperform at CLSA with analyst Michael Lavery saying British American Tobacco's (BTI) $56.50 offer for Reynolds is a moving target and is now worth $55.50. 5. FireEye (FEYE) downgraded to Underweight from Equal-Weight at First Analysis with analyst Howard Smith saying the security spending environment favors other players in the space. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/04/16
OPCO
11/04/16
NO CHANGE
Target $28
OPCO
Outperform
FireEye price target lowered to $28 from $33 at Oppenheimer
Oppenheimer analyst Shaul Eyal lowered his price target for FireEye to $28 from $33 on valuation. Following the company's "solid" Q3 results, the analyst is encouraged by the ongoing operational improvement as well as overall demand and product trends. Further, Eyal says it appears that FireEye's management team "has turned a corner steering it in the right direction." The analyst reiterates an Outperform rating on the shares.
10/21/16
FANA
10/21/16
DOWNGRADE
Target $11
FANA
Underweight
FireEye downgraded to Underweight from Equal-Weight at First Analysis
First Analysis analyst Howard Smith downgraded FireEye to Underweight saying the security spending environment favors other players in the space. The company's high cash burn will drive share underperformance, Smith tells investors in a research note. He cut his price target for the stock to $11 from $15. FireEye closed the trading day up 36c to $12.64.
11/22/16
GSCO
11/22/16
DOWNGRADE
Target $11
GSCO
Sell
FireEye downgraded to Sell from Neutral at Goldman
Goldman analyst Gabriela Borges downgraded FireEye to Sell and lowered its price target to $11 from $15. The analyst said the Street is underestimating medium near-term risk from several product and business model transitions. He expects margins to remain pressured in 2017 due to changes in customer buying patterns and believes FireEye's move into the mid-market will be difficult to execute.

TODAY'S FREE FLY STORIES

JUNO

Juno Therapeutics

$20.43

0.53 (2.66%)

, KITE

Kite Pharma

$50.76

0.04 (0.08%)

21:25
12/03/16
12/03
21:25
12/03/16
21:25
Conference/Events
Canaccord biotech analyst to hold a dinner meeting »

In conjunction with the…

JUNO

Juno Therapeutics

$20.43

0.53 (2.66%)

KITE

Kite Pharma

$50.76

0.04 (0.08%)

BLUE

bluebird bio

$69.75

1.1 (1.60%)

NVS

Novartis

$68.17

0.42 (0.62%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Dec

  • 03

    Dec

  • 06

    Dec

09:15
12/03/16
12/03
09:15
12/03/16
09:15
General news
Breaking General news story  »

New York Federal Reserve…

09:15
12/03/16
12/03
09:15
12/03/16
09:15
General news
Breaking General news story  »

New York Federal Reserve…

04:55
12/03/16
12/03
04:55
12/03/16
04:55
General news
Breaking General news story  »

New York Federal Reserve…

04:55
12/03/16
12/03
04:55
12/03/16
04:55
General news
Breaking General news story  »

New York Federal Reserve…

BMRN

BioMarin

$82.21

-1.12 (-1.34%)

, ESALY

Eisai

$57.91

0.59 (1.03%)

04:55
12/03/16
12/03
04:55
12/03/16
04:55
Conference/Events
American Epilepsy Society to hold annual meeting »

70th Annual Meeting of…

BMRN

BioMarin

$82.21

-1.12 (-1.34%)

ESALY

Eisai

$57.91

0.59 (1.03%)

GWPH

GW Pharmaceuticals

$112.32

3.04 (2.78%)

IART

Integra LifeSciences

$75.78

-1.07 (-1.39%)

MDT

Medtronic

$72.01

0.13 (0.18%)

MNK

Mallinckrodt

$53.61

0.51 (0.96%)

NVTA

Invitae

$6.95

0.16 (2.36%)

SAGE

SAGE Therapeutics

$49.02

-0.23 (-0.47%)

WTKWY

Wolters Kluwer

$34.08

-0.39 (-1.13%)

ZGNX

Zogenix

$13.05

0.35 (2.76%)

ZYNE

Zynerba

$13.64

0.83 (6.48%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Dec

  • 05

    Dec

  • 06

    Dec

  • 07

    Dec

  • 12

    Dec

  • 14

    Dec

  • 28

    Jan

  • 27

    Apr

WMT

Wal-Mart

$70.88

0.21 (0.30%)

18:17
12/02/16
12/02
18:17
12/02/16
18:17
Periodicals
Wal-Mart to pay $7.5M to settle same-sex spouse benefit case, Reuters reports »

Wal-Mart said it would…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GMED

Globus Medical

$21.89

0.12 (0.55%)

, TLN

Talen Energy

18:14
12/02/16
12/02
18:14
12/02/16
18:14
Hot Stocks
S&P announces changes to S&P MidCap 400, S&P SmallCap 600 indices »

S&P Dow Jones Indices…

GMED

Globus Medical

$21.89

0.12 (0.55%)

TLN

Talen Energy

UMBF

UMB Financial

$77.00

-0.43 (-0.56%)

IM

Ingram Micro

$38.88

1.31 (3.49%)

HMST

HomeStreet

$29.35

-0.2 (-0.68%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNJ

Johnson & Johnson

$111.96

0.58 (0.52%)

, ALIOF

Actelion

$206.01

15.21 (7.97%)

18:11
12/02/16
12/02
18:11
12/02/16
18:11
Periodicals
Johnson & Johnson said to raise offer for Actelion above $250, Bloomberg says »

Johnson &…

JNJ

Johnson & Johnson

$111.96

0.58 (0.52%)

ALIOF

Actelion

$206.01

15.21 (7.97%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CE

Celanese

$79.10

0.3 (0.38%)

18:00
12/02/16
12/02
18:00
12/02/16
18:00
Hot Stocks
Celanese to raise list, off-list selling prices for paraformaldehyde »

Celanese Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HMST

HomeStreet

$29.35

-0.2 (-0.68%)

, GMED

Globus Medical

$21.89

0.12 (0.55%)

17:56
12/02/16
12/02
17:56
12/02/16
17:56
Hot Stocks
On The Fly: After Hours Movers »

HIGHER: HomeStreet…

HMST

HomeStreet

$29.35

-0.2 (-0.68%)

GMED

Globus Medical

$21.89

0.12 (0.55%)

BGS

B&G Foods

$42.50

0.2 (0.47%)

ZEN

Zendesk

$21.17

0.34 (1.63%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

  • 09

    Jan

ZEN

Zendesk

$21.17

0.34 (1.63%)

17:53
12/02/16
12/02
17:53
12/02/16
17:53
Hot Stocks
Zendesk says SVPs Amanda Kleha and Marcus Bragg to resign »

On November 29, Amanda…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

AIXG

Aixtron

$3.97

-0.05 (-1.24%)

17:42
12/02/16
12/02
17:42
12/02/16
17:42
Periodicals
President Obama blocks China's Fujian from acquiring Aixtron, CNBC reports »

President Barack Obama…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CX

CEMEX

$7.83

0.09 (1.16%)

17:31
12/02/16
12/02
17:31
12/02/16
17:31
Hot Stocks
CEMEX to divest ready-mix concrete pumping assets in Mexico »

CEMEX announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SRNE

Sorrento Therapeutics

$5.15

-0.1 (-1.90%)

17:30
12/02/16
12/02
17:30
12/02/16
17:30
Syndicate
Breaking Syndicate news story on Sorrento Therapeutics »

Sorrento files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

MBRX

Moleculin Biotech

$2.63

-0.14 (-5.05%)

17:29
12/02/16
12/02
17:29
12/02/16
17:29
Syndicate
Breaking Syndicate news story on Moleculin Biotech »

Moleculin Biotech files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

NEOG

Neogen

$61.59

-1.46 (-2.32%)

17:28
12/02/16
12/02
17:28
12/02/16
17:28
Hot Stocks
Neogen acquires U.K.-based Quat-Chem, terms undisclosed »

Neogen announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RRC

Range Resources

$36.36

-0.23 (-0.63%)

17:25
12/02/16
12/02
17:25
12/02/16
17:25
Hot Stocks
Breaking Hot Stocks news story on Range Resources »

SailingStone Capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EOG

EOG Resources

$103.74

-1.01 (-0.96%)

17:25
12/02/16
12/02
17:25
12/02/16
17:25
Syndicate
Breaking Syndicate news story on EOG Resources »

EOG Resources files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

HMST

HomeStreet

$29.35

-0.2 (-0.68%)

, UMBF

UMB Financial

$77.00

-0.43 (-0.56%)

17:22
12/02/16
12/02
17:22
12/02/16
17:22
Hot Stocks
Breaking Hot Stocks news story on HomeStreet, UMB Financial »

HomeStreet to replace UMB…

HMST

HomeStreet

$29.35

-0.2 (-0.68%)

UMBF

UMB Financial

$77.00

-0.43 (-0.56%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UMBF

UMB Financial

$77.00

-0.43 (-0.56%)

, IM

Ingram Micro

$38.88

1.31 (3.49%)

17:21
12/02/16
12/02
17:21
12/02/16
17:21
Hot Stocks
UMB Financial to replace Ingram Micro in S&P 400 as of 12/6 close »

Tianjin Tianhai…

UMBF

UMB Financial

$77.00

-0.43 (-0.56%)

IM

Ingram Micro

$38.88

1.31 (3.49%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GMED

Globus Medical

$21.89

0.12 (0.55%)

, TLN

Talen Energy

17:20
12/02/16
12/02
17:20
12/02/16
17:20
Hot Stocks
Globus Medical to replace Talen Energy in S&P 400 as of 12/6 close »

Riverstone Holdings is…

GMED

Globus Medical

$21.89

0.12 (0.55%)

TLN

Talen Energy

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AIXG

Aixtron

$3.97

-0.05 (-1.24%)

17:16
12/02/16
12/02
17:16
12/02/16
17:16
Periodicals
President Obama blocks China's takeover of Aixtron, CNBC reports »

Says the transaction…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DB

Deutsche Bank

$15.74

-0.32 (-1.99%)

17:07
12/02/16
12/02
17:07
12/02/16
17:07
Periodicals
Deutsche Bank to pay $60M settlement over gold price-fixing case, Reuters says »

Deutsche Bank will pay…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Jan

ALB

Albemarle

$84.86

-0.79 (-0.92%)

17:07
12/02/16
12/02
17:07
12/02/16
17:07
Hot Stocks
Albemarle to increase prices for select brominated products »

Albemarle announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.